Endgame 2024: imagining a world with dengue control
Wednesday, August 7, 2024
8:00am – 8:45am Arrival, registration, and coffee
8:45am – 9:00am Welcome and introductions
9:00am – 10:00am Session #1. Reality check: current state of dengue on the ground
Objective: to discuss and review the current state of dengue around the world
Jeremy Farrar, DPhil (WHO)
“Welcome, and the current state of dengue”
Laura Adams, DVM, MPH (CDC Dengue Branch):
“Dengue in the United States”
10:00am – 10:20am Coffee break
10:20am – 12:00pm Session #2. Can we talk? Immunologic crosstalk between flaviviruses
Objective: to review and discuss our current understanding of the impact of immunologic crosstalk between flaviviruses as it pertains to DENV pathogenesis and countermeasure efficacy
Kathryn Anderson, MD PhD (SUNY Upstate Medical University):
“Deciphering the signal in the noise for dengue virus immunity through long-term cohort studies”
Giovanna Barba Spaeth, PhD (Institut Pasteur):
“Flavivirus cross-talk: the impact of vaccination”
Mattia Bonsignori, MD (NIH)
“Functional B cell cross-reactivity profiling in Rhesus macaques upon sequential zika and dengue virus infections”
Daniela Weiskopf, PhD (LJI):
“Cross-reactivity between flavivirus specific T cells”
Moderated discussion: Alan Rothman, MD (University of Rhode Island)
12:00pm – 1:00pm Lunch Break (boxed lunch)
1:00pm – 1:40pm Session #3. The changing face of dengue
Objective: to discuss and review the shifting clinical burden of dengue
Derek Cummings, PhD (JHU):
“Shifting burdens of dengue across the globe”
Eng Eong Ooi, MD PhD (Duke-NUS):
“Dengue burden - new trends bring new uncertainties”
Moderated discussion: Kathryn Anderson, MD PhD (SUNY Upstate)
1:40pm – 2:00pm Coffee break
2:00pm – 3:20pm Session #4. Signatures of DENV immunity & pathogenesis
Objective: to discuss advances in our understand of dengue pathogenesis and biomarkers of disease severity
Ernesto Marques, MD (University of Pittsburgh):
“The complement system in dengue infection: friend and foe”
Adam Waickman, PhD (SUNY Upstate Medical University):
“BCR-dependent enhancement of dengue virus infection”
Taia Wang, MD, PhD (Stanford)
“A fresh look at predicting dengue immunity”
Moderated discussion: Ashley St. John, PhD (Duke NUS)
3:20pm – 3:40pm Coffee break
3:40am – 4:20pm Keynote presentation: Scott Halstead, MD
“Dengue: confronting the pandemic”
4:20pm – 4:30pm Closing remarks, day 1
4:30pm – 6:00pm Happy hour and poster session (Grand Hall)
Thursday, August 8, 2024
8:00am – 8:30am Arrival and coffee
8:30am – 8:40am Welcome and recap of Day 1
8:40am – 10:20am Session #5. Advances in preclinical & clinical models for assessing dengue countermeasures
Objective: to discuss advances in models to assess/predict dengue countermeasure efficacy and how these models/tools can support regulatory decisions/requirements
Kirk Prutzman, PhD (FDA):
Regulatory considerations for preclinical and clinical models for dengue vaccine evaluation
Alan Barrett, PhD (UTMB):
Preclinical animal models for assessing dengue countermeasures
Stephen Thomas, MD (SUNY Upstate):
Lessons Learned from the Dengue Human Infection Model Consortium
Beth Kirkpatrick, MD (UVM):
Use of human challenge models for vaccine evaluation
Moderated discussion: Nelson Michael, MD PhD (WRAIR)
10:20am – 10:40am Coffee break
10:40am – 12:00pm Session #6. Advances in dengue diagnostics and risk prediction: implications for dengue mitigation and management
Objective: to discuss and review recent advances in dengue diagnostics and surveillance technology and implications for countermeasure deployment
Frank Middleton, PhD (SUNY Upstate):
“Comparative Performance of Optimized Saliva-Based Nucleic Acid Detection and Quantification of Dengue”
Priscila Da Silva Castanha, PhD MPH (University of Pittsburgh):
Discovery of Biomarkers via Epitope Surrogate Technology: a novel approach for differential serodiagnosis between Zika and dengue viral infections.
Bridget Wills, MD (OUCRU):
Characterizing the features of clinical dengue – seeing the big picture
Moderated discussion: Alan Landay, PhD (UTMB)
12:00pm – 1:00pm Lunch Break (boxed lunch)
1:00pm – 2:20pm Session #7. Vectors, vector control, and vector-directed interventions
Objective: to discuss and review the current state of vector control technology and vector-directed interventions and their implication for dengue control
Rebecca Christofferson, PhD (LSU)
“Vectors and vector control: historical challenges and modern solutions”
George Dimopoulos, PhD (JHU SPH):
“Exploiting Aedes – arbovirus interactions for disease control”
Fabiano Oliverira, MD PhD (NIH):
“Antibodies to Aedes aegypti D7L salivary proteins as a tool to estimate human exposure to Aedes mosquitoes”
Moderated discussion: Saravanan Thangamani, PhD (SUNY Upstate)
2:20pm – 2:40pm Coffee break
2:40pm – 3:40pm Session #8. Next-generation countermeasures
Objective: to review and discuss the state of next-generation dengue countermeasures
Lillian Chiang (EvrysBio):
Human sirtuin 2 protein, an intrinsic immunity target for medical countermeasure development
Phil Santangelo, PhD (Emory/Georgia Tech):
Treating dengue infections with mRNA-encoded Cas13
Moderated discussion: Aaron Farmer, DO (AFRIMS)
3:40pm – 4:00pm Break
4:00pm – 5:00pm Session #9. Advanced countermeasure update
Objective: Objective: to review and discuss clinical stage dengue countermeasures deployment and evaluation
Shibadas Biswal, MBBS (Takeda):
Update on rollout of Takeda's dengue vaccine and post-licensure plan
Bhagwat Gunale, MD (SII)
“Update on Phase 2 clinical trial of Dengue monoclonal antibody”
Guillermo Herrera-Taracena, MD, MBA (JnJ)
“Latest Insights from a Phase 2 Dengue Prophylactic study with JNJ-1802 -Mosnodenvir: An Overview of Preliminary Baseline Data”
Moderator: Albert Ko, MD (Yale)
5:00pm – 5:40pm Session #10. Roundtable discussion: challenges and opportunities in dengue countermeasure development and deployment during a dengue epidemic
Objective: Objective: to review and discuss clinical stage dengue countermeasures deployment and evaluation
Guillermo Herrera-Taracena, MD, MBA (JnJ)
Prasad Kulkarni, MD (SII)
Louis Macareo, MD, JD (Merck):
Kirk Prutzman, PhD (FDA)
Derek Wallace, PhD (Takeda)
Moderator: Stephen Thomas, MD (SUNY Upstate)
5:40pm – 6:00pm Closing remarks, day 2
Friday, August 9, 2024
8:00am – 8:30am Arrival and coffee
8:30am – 8:40am Welcome and recap of Day 1
8:40am – 9:40am Session #11. Reading between the lines: supporting countermeasure development and deployment decisions with imperfect data
Objective: to discuss how advances in epidemiologic and immunologic models can inform policy and countermeasure deployment decisions in the absence of perfect data
Alex Perkins, PhD (ND):
Sustainable control of dengue will require coordinated deployment of multiple approaches
Ilaria Dorigatti, PhD (Imperial College London):
Challenges and opportunities in modelling dengue interventions
Moderated discussion: Michael Johansson, PhD (CDC)
9:40am – 10:00am Break
10:00am – 11:20am Session #12. Vaccines alone don’t save lives… addressing vaccine hesitancy and scientific misinformation in support of a dengue endgame
Objective: to discuss challenges and opportunities in dengue-related policy and communication
Telisa Stewart, MPH DrPH (SUNY Upstate):
“Communication and Behavioral Health Vaccination Playbook – Patients and Populations”
Jana Shaw, MD (SUNY Upstate):
“From Doubt to Trust: Strategies to Combat Vaccine Hesitancy in the United States”
Hoe Nam Leong, MD (Singapore):
Dengue Vaccines - Asian Perspectives
Moderated discussion: Rebecca Christofferson, PhD (LSU)
11:20am – 11:30am Closing remarks